Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065645 | 0.92 | SIRT2 (0.40) | NMBRSIRT2REN | |
| SCHEMBL29549611 | 0.90 | SIRT2 (0.37) | NMBRSIRT2 | |
| SCHEMBL31094172 | 0.90 | NMBR (0.38) | NMBRSIRT2REN | |
| SCHEMBL30641716 | 0.89 | PTPN1 (0.40) | NMBRSIRT2 | |
| SCHEMBL31094168 | 0.87 | REN (0.38) | NMBRSIRT2RENCTSSCTSL | |
| SCHEMBL29427178 | 0.85 | NMBR (0.51) | NMBRSIRT2CTSSCTSLCTSB | |
| SCHEMBL29427176 | 0.85 | NMBR (0.51) | NMBRSIRT2CTSSCTSLCTSB | |
| SCHEMBL30665993 | 0.84 | NMBR (0.44) | NMBRSIRT2CTSSCTSLCTSB | |
| SCHEMBL30277394 | 0.84 | NMBR (0.44) | NMBRSIRT2RENCTSS | |
| SCHEMBL30782930 | 0.82 | ACE (0.40) | SIRT2CTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324936-A1 | PROCESS FOR THE MANUFACTURE OF GLUCAGON | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-10-13 | — | — | US | claimed |
| EP-3986919-A1 | PROCESS FOR THE MANUFACTURE OF GLUCAGON | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-04-27 | — | — | EP | claimed |
| CN-114401981-A | Process for producing glucagon | 北京费森尤斯卡比医药有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-114401981-B | Glucagon production method | 北京费森尤斯卡比医药有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-115975057-B | Solid phase synthesis method of trastuzumab | 杭州信海医药科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115975057-B | Solid phase synthesis method of trastuzumab | 杭州信海医药科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115975057-A | Solid-phase synthesis method of clodotoxin | 杭州信海医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115975057-A | Solid-phase synthesis method of clodotoxin | 杭州信海医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220324936-A1 | PROCESS FOR THE MANUFACTURE OF GLUCAGON | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-10-13 | — | — | US | disclosed |
| EP-3986919-A1 | PROCESS FOR THE MANUFACTURE OF GLUCAGON | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-04-27 | — | — | EP | disclosed |
| CN-114401981-A | Process for producing glucagon | 北京费森尤斯卡比医药有限公司 | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324936-A1 | PROCESS FOR THE MANUFACTURE OF GLUCAGON | IAPP, GCG, GLP1R | NMBR 1421/4885SIRT2 4064/4885REN 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.